Wiley-VCH, Weinheim Inducing Targeted Protein Degradation Cover The guide to induced protein degradation for drug developers in academia and industry surveys establ.. Product #: 978-3-527-35013-1 Regular price: $139.25 $139.25 Auf Lager

Inducing Targeted Protein Degradation

From Chemical Biology to Drug Discovery and Clinical Applications

Cromm, Philipp (Herausgeber)


1. Auflage Dezember 2022
384 Seiten, Hardcover
93 Abbildungen (68 Farbabbildungen)

ISBN: 978-3-527-35013-1
Wiley-VCH, Weinheim


The guide to induced protein degradation for drug developers in academia and industry surveys established and novel approaches in the field, with an eye on expanding the range of druggable targets.

Jetzt kaufen

Preis: 149,00 €

Preis inkl. MwSt, zzgl. Versand

Weitere Versionen

Targeted Protein Degradation - The Story So Far
Cellular Principles of Targeted Protein Degradation
E3 Ubiquitin Ligases as Molecular Machines and Platforms for Drug Development
A Structural and Biophysical Perspective of Degrader Activity through Ternary Complex Formation
Computational Modeling of PROTAC Ternary Complexes and Linker Design
Molecular Glue Degraders: From Serendipity to Hunting and Design
Targeted Protein Degradation as a Therapeutic Strategy in Neurodegenerative Diseases
Insights and Future Perspectives of Covalent Protein Degraders
Extending the Degradation Toolkit - mRNA targeting as Alternative Means to Affect Protein Levels
The Future of Heterobifunctional Compounds: PROTACs and Beyond
Destruction with a Purpose: Targeted Protein Degradation in Drug Discovery
Taming the Beast: How to Optimize DMPK-PD Properties of Oral Degraders
PROTAC® Protein Degraders: Bridging the Divide from Chemical Biology Tools to Clinical Candidates
Philipp M. Cromm studied Chemistry at the Technical University Munich where he worked in the group of Horst Kessler. For his master's thesis he spent time with David J. Craik at the Institute for Molecular Bioscience and received his PhD under guidance of Herbert Waldmann at the Max-Planck-Institute for Molecular Physiology. Thereafter, he carried out postdoctoral studies in the group of Craig Crews at Yale University working on targeted protein degradation. In 2018 Philipp joined Bayer AG as a Medicinal Chemist.